^
No biomarker
Oropharyngeal Cancer
TPF
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
cisplatin + paclitaxel
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
afatinib
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
capecitabine
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
methotrexate
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
5-fluorouracil
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
docetaxel
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
paclitaxel
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
carboplatin
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
cetuximab
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
cisplatin + docetaxel
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
nivolumab
Sensitive
:
A2
PD-L1 expression
Oropharyngeal Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
cisplatin + paclitaxel + 5-fluorouracil
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
cisplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
5-fluorouracil + hydroxyurea
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
carboplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
cisplatin
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
pembrolizumab + cetuximab
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
pembrolizumab
Sensitive
:
A2
ITGAE overexpression
Oropharyngeal Cancer
cetuximab
Sensitive
:
C3